Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib and Ruxolitinib in Hypereosinophilic Syndrome
NCT00044304Phase 2Active, not recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2002
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of imatinib and ruxolitinib in hypereosinophilic syndrome (HES) and myeloid neoplasm with eosinophilia (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Peripheral blood absolute eosinophil count at 3 months. Started Sep 2002; status: active, not recruiting.
02
Drugs
03
Conditions
hypereosinophilic syndrome (HES)myeloid neoplasm with eosinophilia
Beyond the preview
Go deeper on NCT00044304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00044304.